Summary
Cell immunotherapy is a breakthrough treatment that uses immune cells to directly attack tumours. It is considered the most
exciting development in cancer treatment in years. When it works, patients with life-threatening cancers live far longer or
may even be cured. But so far, immunotherapy only works for few types of cancer and few patients, and finding the most
effective immune cells is still an immense challenge.
LUMICKS is developing z-Movi, the first high-throughput platform that screens and sorts immune cells based on their
functionality using non-invasive techniques. z-Movi is a unique and powerful solution that now allows researchers to look at
thousands of immune cells and find the right ones within a couple of minutes – a process that would take months with
standard technologies. Therefore, z-Movi is the perfect R&D tool to help and speed up the process of bringing new
immunotherapy treatments to market. z-Movi is expected to disrupt the immunotherapy market, which is mostly driven by
innovation and is expected to reach €100B by 2021.
LUMICKS started by teaming-up with immunotherapy leaders such as the Dutch Cancer Institute and Institut Pasteur to
develop z-Movi. The first developed z-Movi was already introduced to early adopters. After completing optimisation, a new
generation z-Movi will target the immunology research institutes, biotech and pharma markets. Users from those segments
have already demonstrated concrete interest in our solution, or are in the process of acquisition. The incremental z-Movi
revenue stream from this EIC Accelerator project will be around €20M by 2022 and the net profit margin will double.
LUMICKS’ post-EIC ultimate goal is to go beyond the
exciting development in cancer treatment in years. When it works, patients with life-threatening cancers live far longer or
may even be cured. But so far, immunotherapy only works for few types of cancer and few patients, and finding the most
effective immune cells is still an immense challenge.
LUMICKS is developing z-Movi, the first high-throughput platform that screens and sorts immune cells based on their
functionality using non-invasive techniques. z-Movi is a unique and powerful solution that now allows researchers to look at
thousands of immune cells and find the right ones within a couple of minutes – a process that would take months with
standard technologies. Therefore, z-Movi is the perfect R&D tool to help and speed up the process of bringing new
immunotherapy treatments to market. z-Movi is expected to disrupt the immunotherapy market, which is mostly driven by
innovation and is expected to reach €100B by 2021.
LUMICKS started by teaming-up with immunotherapy leaders such as the Dutch Cancer Institute and Institut Pasteur to
develop z-Movi. The first developed z-Movi was already introduced to early adopters. After completing optimisation, a new
generation z-Movi will target the immunology research institutes, biotech and pharma markets. Users from those segments
have already demonstrated concrete interest in our solution, or are in the process of acquisition. The incremental z-Movi
revenue stream from this EIC Accelerator project will be around €20M by 2022 and the net profit margin will double.
LUMICKS’ post-EIC ultimate goal is to go beyond the
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/961442 |
Start date: | 01-10-2020 |
End date: | 30-09-2022 |
Total budget - Public funding: | 2 875 000,00 Euro - 2 012 500,00 Euro |
Cordis data
Original description
Cell immunotherapy is a breakthrough treatment that uses immune cells to directly attack tumours. It is considered the mostexciting development in cancer treatment in years. When it works, patients with life-threatening cancers live far longer or
may even be cured. But so far, immunotherapy only works for few types of cancer and few patients, and finding the most
effective immune cells is still an immense challenge.
LUMICKS is developing z-Movi, the first high-throughput platform that screens and sorts immune cells based on their
functionality using non-invasive techniques. z-Movi is a unique and powerful solution that now allows researchers to look at
thousands of immune cells and find the right ones within a couple of minutes – a process that would take months with
standard technologies. Therefore, z-Movi is the perfect R&D tool to help and speed up the process of bringing new
immunotherapy treatments to market. z-Movi is expected to disrupt the immunotherapy market, which is mostly driven by
innovation and is expected to reach €100B by 2021.
LUMICKS started by teaming-up with immunotherapy leaders such as the Dutch Cancer Institute and Institut Pasteur to
develop z-Movi. The first developed z-Movi was already introduced to early adopters. After completing optimisation, a new
generation z-Movi will target the immunology research institutes, biotech and pharma markets. Users from those segments
have already demonstrated concrete interest in our solution, or are in the process of acquisition. The incremental z-Movi
revenue stream from this EIC Accelerator project will be around €20M by 2022 and the net profit margin will double.
LUMICKS’ post-EIC ultimate goal is to go beyond the
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all